3 news items
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
TEVA
1 Jun 24
to early 30s for women.4 The long-term course of schizophrenia is marked by episodes of partial or full
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
TEVA
8 May 24
, the average age of onset tends to be in the late teens to the early 20s for men, and the late 20s to early 30s for women
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
TEVA
6 Apr 24
for men, and the late 20s to early 30s for women.3 The long-term course of schizophrenia is marked
- Prev
- 1
- Next